Iovance Biotherapeutics, Inc. (IOVA)
What's Wrong With Iovance Biotherapeutics Stock?
It was about a year ago that shares of Iovance Biotherapeutics (IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as a treatment option for patients with unresectable or metastatic melanoma.
Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company has encountered some success, including a crucial regulatory approval coming down last year, that hasn't been enough to seduce investors.
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that produces dramatic market movements.
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price.
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise.
Prediction: This Stock Will Beat the Market in 2025
It hasn't been a great year for Iovance Biotherapeutics (IOVA -1.40%), an innovative mid-cap biotech company. The drugmaker's shares have significantly lagged the market -- advancing only about 5% so far this year.
3 Monster Stocks to Hold for the Next 10 Years
It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story.
Is Iovance Biotherapeutics Stock a Millionaire Maker?
The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop and commercialize a life-changing therapeutic, countless more start-ups inevitably fail.
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
As the rising star of cell therapy biotechs, Iovance Biotherapeutics (IOVA 3.76%) is a hot stock that's capturing a lot of attention, and for good reason. Iovance's one-of-a-kind medicine is already selling like hotcakes, and there's reason to believe that plenty more growth is on the way.
2 Innovative Stocks That Could Deliver Outsize Returns
2 Innovative Stocks That Could Deliver Outsize Returns
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors.
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
